Sangamo Therapeutics

Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

All edits

Edits on 30 April, 2020
Nico Faraguna
Nico Faraguna edited on 30 April, 2020 9:29 pm
Edits made to:
Infobox (--1 properties)

Infobox

B2X
Edits on 16 October, 2019
Edita Rexha"Approved suggestion #660575"
Edita Rexha edited on 16 October, 2019 10:37 am
Edits made to:
Article

Article

Edits on 27 April, 2019
Mevludin Mešanović
Mevludin Mešanović approved a suggestion from Golden's AI on 27 April, 2019 3:42 pm
Edits made to:
Infobox (+1 properties)
Edits on 4 April, 2019
Dawson Sewell
Dawson Sewell edited on 4 April, 2019 9:09 pm
Edits made to:
Infobox (+6 properties)
Article (+1092/-762 characters)
Further reading (+3 cells) (+40 characters)
Categories (+1 topics)
Related Topics (+2 topics)

Article

Sangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body.

Sangamo Therapeutics is a biotechnology company developing gene and cell therapies using genetic engineering that is headquartered in Richmond, California and founded in 1995 by Edward Lanphier.

...

Sangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body.

Funding

Grant

On February 7, 2018 Sangamo Therapeutics received a grant worth $11 million from the National Institutes of Health (NIH).

Further reading

Title
Author
Link
Type

AP Exclusive: US scientists try 1st gene editing in the body

Marilynn Marchione

Web

Man 'cured' of HIV through gene editing holds hope for others

Associated Press

Web

Infobox

Categories

Related Topics

Edits on 22 March, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 22 March, 2019 1:14 pm
Edits made to:
Article (+15/-15 characters)

Article

Sangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndromeHunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body.

Edits on 14 March, 2019
Dawson Sewell
Dawson Sewell edited on 14 March, 2019 3:22 pm
Edits made to:
Infobox (+3 properties)
Edits on 25 February, 2019
Meredith Hanel
Meredith Hanel edited on 25 February, 2019 5:31 pm
Edits made to:
Companies (+1 rows) (+1 cells) (+6 characters)

Companies

Company
CEO
Location
Products/Services

TxCell

Edits on 22 February, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 22 February, 2019 8:13 pm
Edits made to:
Article (+3/-3 characters)

Article

Sangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIVHIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body.

Edits on 12 February, 2019
Meredith Hanel
Meredith Hanel edited on 12 February, 2019 8:34 pm
Edits made to:
Article (+209/-113 characters)

Article

ScientistsSangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo were the first to edit human cells and the first to conductconducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology. Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body.

Meredith Hanel
Meredith Hanel edited on 12 February, 2019 8:00 pm
Edits made to:
Article (+418 characters)

Article

Scientists at Sangamo were the first to edit human cells and the first to conduct clinical trials with gene edited T cells. In 2018, they initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology. Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 12 February, 2019 6:41 pm
Edits made to:
Article (+15/-15 characters)

Article

Scientists at Sangamo were the first to edit human cells and the first to conduct clinical trialsclinical trials with gene edited T cells. In 2018, they initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology.

Jude Gomila
Jude Gomila edited on 12 February, 2019 6:39 pm
Edits made to:
Article (+11/-10 characters)

Article

Scientists at Sangamo were the first to edit human cells and the first to conduct clinical trials with gene edited T cells. RecentlyIn 2018, wethey initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology.

Edits on 12 February, 2019
Meredith Hanel
Meredith Hanel edited on 12 February, 2019 2:34 pm
Edits made to:
Infobox (+9 properties)
Description (+99 characters)
Article (+247 characters)
People (+2 rows) (+4 cells) (+146/-11 characters)
Further reading (+1 rows) (+3 cells) (+154 characters)
Categories (+2 topics)
Related Topics (+2 topics)
Topic thumbnail

Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

Article

Scientists at Sangamo were the first to edit human cells and the first to conduct clinical trials with gene edited T cells. Recently, we initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology.

People

Name
Role
Related Golden topics

Heather Turner, JD

Senior Vice President and General Counsel

Sandy Macrae, M.B., Ch.B., Ph.D

CEO

Sandy MacraeStephane Boissel

Executive Vice President Corporate Strategies

Further reading

Title
Author
Link
Type

Man 'cured' of HIV through gene editing holds hope for others

Web

Infobox

Categories

Related Topics

Edits on 8 June, 2018
Carla Faraguna
Carla Faraguna edited on 8 June, 2018 11:03 pm
Edits made to:
People (+1 rows) (+2 cells) (+21 characters)
Further reading (+1 rows) (+2 cells) (+115 characters)
Related Topics (+1 topics)

Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

People

Name
Role
Related Golden topics

Sandy Macrae

President

Further reading

Author
Title
Link
Type

AP Exclusive: US scientists try 1st gene editing in the body

Related Topics

Carla Faraguna"Initial topic creation"
Carla Faraguna created this topic on 8 June, 2018 11:00 pm
Edits made to:
Topic thumbnail

 Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

No more activity to show.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.